Huntington National Bank Sells 71,695 Shares of Pfizer Inc. (NYSE:PFE)

Huntington National Bank lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 668,660 shares of the biopharmaceutical company's stock after selling 71,695 shares during the period. Huntington National Bank's holdings in Pfizer were worth $17,740,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PFE. United Bank boosted its position in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after acquiring an additional 1,277 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Pfizer by 5.2% during the third quarter. HighTower Advisors LLC now owns 3,219,490 shares of the biopharmaceutical company's stock valued at $93,146,000 after purchasing an additional 157,775 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Pfizer by 0.5% in the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company's stock valued at $15,348,000 after purchasing an additional 2,600 shares during the period. Investment Management Corp of Ontario raised its holdings in shares of Pfizer by 49.4% in the 3rd quarter. Investment Management Corp of Ontario now owns 188,144 shares of the biopharmaceutical company's stock worth $5,445,000 after buying an additional 62,200 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its position in shares of Pfizer by 12.1% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 488,757 shares of the biopharmaceutical company's stock worth $14,145,000 after buying an additional 52,662 shares during the period. Institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Trading Down 5.4 %

Pfizer stock traded down $1.30 during mid-day trading on Friday, hitting $22.99. The stock had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The stock has a market capitalization of $130.39 billion, a PE ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a 50-day simple moving average of $25.87 and a two-hundred day simple moving average of $26.74.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 EPS. Pfizer's revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on PFE shares. Bank of America reiterated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.